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Abstract
Background: The incidence of tuberculosis (TB) in developed countries has decreased since the
1990s, reflecting worldwide efforts to identify and treat TB according to WHO recommendations.
However TB remains an important public health problem in industrialized countries with a high
proportion of cases occurring among subjects originating from high prevalence countries. The aim
of this study was to describe clinical and social characteristics of patients with TB and their
outcome in a low incidence area with a high immigration rate.
Methods: Four-year retrospective study based on a computerized database and subsequent
review of medical records of all patients with TB followed at the outpatient section of the Division
of Pulmonary Diseases, Geneva University Hospital, Switzerland.
Results: 252 patients (84% foreigners, 25% asylum seekers) aged 38 ± 19 yrs were studied (11%
co-infected with HIV). TB was intrapulmonary (TBP) in 158 cases (63%), extrapulmonary (TBE) in
137 (54%), and both in 43 cases (17%). TBP was smear (S)+/culture (C)+ in 59%, S-/C+ in 37%, S-
/C- in 4%. Smoking was significantly associated with cavitary disease.
Time from onset of symptoms to diagnosis was 2.1 ± 3.1 months. Initially, 10% were asymptomatic;
35% had no general symptoms. Despite systematic sputum analysis (induced or spontaneous), TBP
was confirmed only by bronchoscopy in 38 subjects (24% of TBP). Side effects requiring changes in
treatment occurred in 38 cases (11%).
Treatment was completed in 210 (83%) patients. In 42 cases, follow up was unsuccessful; causes
were: failure (n = 2; 0.8%), defaulters (n = 8; 3%), transfer out (n = 28; 11%) and death (n = 4; 1.6%).
Relapse rate was 0.24 per 100 patient-years. Considering S+ TBP only, success rate was 87%.
Conclusion: TB in our area is predominantly a disease of young foreign-born subjects. Smoking
appears as a possible risk factor for cavitary TBP. Time to diagnosis remains long. Compliance to
treatment is satisfactory. Success rate for S+ TBP is within WHO objectives.
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With an estimated 9 million new cases and 2 million
deaths every year, tuberculosis (TB) remains a leading
public health problem worldwide [1]. In industrialized
countries, incidence of TB has been regularly decreasing
since the 1990s, although recently, several European
countries have reported a slight increase in TB, mostly
related to young immigrants from high-incidence coun-
tries [2,3].
In Switzerland, incidence of TB is low (8.5 per 100 000
population). Over the past 10 years, as in most countries
of Western Europe, the proportion of indigenous TB cases
has continuously decreased while that of foreigners (pres-
ently 76%) has increased. In recent years, the overall inci-
dence of tuberculosis in Switzerland has stabilized due to
immigration from high prevalence countries [4].
In 1998, the World Health Organization (WHO) and the
International Union Against Tuberculosis and Lung Dis-
ease (IUATLD) published recommendations standardis-
ing the evaluation of treatment outcome for TB in Europe
[5]. Outcome targets set by WHO were to achieve at least
an 85% cure rate and 70% detection of smear positive TB.
Based on a recent meta-analysis, only 75% of TB cases are
successfully treated in Europe, but with a very high heter-
ogeneity in results [6]. The only 3 studies performed in
Switzerland cover 1991 and 1998, and reported a success-
ful outcome in a rather low 79% of TB cases [7-9].
The Geneva area offers a privileged opportunity to study
treatment outcome in a population with a low TB inci-
dence, as almost all cases of TB are supervised by one spe-
cialized centre.
The aim of this study is thus to describe recent clinical and
social characteristics of patients with TB, to analyse treat-
ment outcome and to identify factors associated with
unsuccessful outcome.
Methods
In the Canton of Geneva (450,000 residents), incidence of
TB is 2.5 times above the national average (20 cases per
100,000 inhabitants), mainly because of a higher propor-
tion of foreign-born residents (45% in 2008). Most TB
cases are either diagnosed at Geneva University Hospital
(emergency ward, outpatient or inpatient clinics) and
referred to the outpatient clinic of the Division of Pulmo-
nary Diseases, or directly referred to the Division of Pul-
monary Diseases by private practitioners for treatment
and follow-up. Albeit for asylum seekers, there is no sys-
tematic screening program for TB in our area. All patients
treated for TB are entered in a computerized database
which stores information on gender, age, origin, micro-
biological details, co-morbidities including results of HIV
testing (performed in all cases after informed consent),
diagnosis of previous TB, antimicrobial drug resistance,
chest X-ray findings and treatment prescribed.
Medical records of all cases of TB for whom treatment was
started at our centre between 1.1.1999 and 31.12.2002
were reviewed; compliance and tolerance to treatment
(monthly ASAT: Aspartate amino-transferase; and ALAT:
Alanine amino-transferase, reported side-effects), treat-
ment interruptions and their causes were analyzed. We
excluded cases which were not confirmed by positive cul-
ture or histopathology (n = 30).
Treatment regimens for TB were in agreement with inter-
national guidelines. Default treatment for pulmonary TB
was a four-drug regimen of isoniazide, rifampicine,
ethambutol and pyrazinamide for 2 months followed by
4 months of isoniazide and rifampicine only. Treatments
were administered on a daily basis, or, in case of DOT, 3
times weekly after at least 2 weeks of daily treatment.
Duration of treatment was extended to 12 months in case
of osteo-articular TB, or central nervous system involve-
ment. Incidence of primary resistance to isoniazide in our
area is 4.9% [4]. For patients with smear positive sputum
samples, treatment was initiated during a 2 week hospital
stay, and then pursued on an outpatient basis. The deci-
sion to implement DOT (Directly Observed Therapy) was
left to the discretion of attending physicians. Compliance
was assessed by attendance to monthly visits and urinary
testing for isoniazid (INH). HIV testing was performed in
all patients with TB.
For patients with suspected pulmonary TB, a trial of
induced sputum production was systematically per-
formed by chest therapists whenever spontaneous sputum
samples could not be obtained; when microscopic exam-
ination of samples for acid-fast bacilli (AFB) was negative,
or adequate samples could not be obtained, bronchos-
copy was performed. During the procedure, bronchoalve-
olar lavage (BAL), and bronchial aspirate (BA) were
performed and analysed systematically. Brushings or
biopsies were performed only if indicated by endoscopic
findings. Post-bronchoscopy sputum samples were not
systematically analysed.
The Ethics Committee of Geneva University Hospital
approved the study protocol.
Definitions
Outcome of treatment is reported as follows in agreement
with WHO and IUATLD criteria [5]:
1/successful outcome: treatment completed and assumed
cure with or without microbiological evidence of cure; 2/
unsatisfactory outcome: treatment failure, defaulters,
death or transfer out. The latter category includes patients
who left the country (expelled or not), patients transferredPage 2 of 8
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lowed by a private physician through which information
on treatment outcome could not be obtained.
Following WHO recommendations [5], analysis of out-
come was performed separately for new cases and retreat-
ment cases.
Serious drug-related side effects were defined as those requir-
ing a change in therapy or hospitalization. Biological hep-
atitis was defined as an elevation of ASAT and/or ALAT at
least 5 times above upper limit of normal values.
We defined as general symptoms: fever, weight loss or noc-
turnal sweating. "Any drug resistance" refers to resistance to
one of the first line therapy drugs (isoniazide: INH,
rifampicine, ethambutol, pyrazinamide) while multi-drug
resistance (MDR) is defined by simultaneous resistance to
at least INH and rifampicine.
Statistical analysis
Variables are reported as mean ± standard deviation (SD).
Comparison between groups was performed using
unpaired t tests, chi-square tests or Fischer's exact test
when appropriate. Multiple logistic regressions were per-
formed to analyse the relationship between independent
variables selected by a stepwise backward analysis and
specific dependant variables. The results are presented as
odds ratios (OR) with 95% confidence intervals (95%CI).
P values < 0.05 were considered statistically significant.
Statistical analyses were performed with Stata Statistical
Software for PC computers (version 10.1, 2007; Stata Cor-
poration, College Station, Texas, USA).
Results
Patients
Between January 1999 and December 2003, 252 patients
(120 male: 47%; 132 female: 53%; aged 38 ± 19 yrs;
range: 15-92) were eligible and included in the present
study. This represents 78.5% of all cases of TB treated in
the Geneva area during the same period (irrespective of
bacteriological confirmation). Of these 252 patients, 84%
were foreign-born. Socio-demographic characteristics of
patients and risk factors for TB are listed in table 1.
Foreign-born patients were on average younger (35.1 ±
15.0 yrs, range: 15-88) than indigenous patients (62.5 ±
19.3 yrs, range 23-92) (Figure 1). However, figure 1 shows
a bi-modal distribution of indigenous patients with a
group of younger patients (n = 17, aged < 50 years) which
had a very high rate of HIV co-infection (47%) when com-
pared to foreign-born subjects of the same age group (n =
164, 11.6%, p = .001; Fisher's exact test)
Foreign-born patients originated mainly from Africa
(38.4%), Europe (19.3%), Latin America (8.5%), and Asia
(9.5%). Fifteen cases (6%) were diagnosed through sys-
tematic screening of asylum seekers at the border (chest X-
ray). Only 4 cases (1.5%) were detected in contact-tracing
procedures (0.2% of 2095 subjects screened)[10]. Twenty-
eight cases (11%) were co-infected with HIV: only 3 were
on antiretroviral therapy at diagnosis (Table 1).
Table 1: Socio-demographic characteristics of patients
n = 252 n (%)
Ethnic origin
• Caucasian 98 (39)
• Asian 20 (8)
• Hispanic 39 (15)
• Black 95 (38)
Socioeconomic status
• Asylum seekers 66 (26)
• Political refugees 18 (7)
• Illegal status 12 (5)
• Homeless 2 (1)
Immunosuppression
• Co-infection with HIV 28 (11)
CD4 lymphocyte count (/mm3)
 > 500 5 (18)*
 200 - 500 5 (18)*
 50 - 200 10 (36)*
 < 50 8 (28)*
• Immunosuppressive treatment 3 (2)
Substance abuse
• Active smokers 46 (18)
• Alcohol abuse 16 (6)
• Drug abuse 6 (2)
Prior TB 10 (4)
HIV = Human immune-deficiency virus; TB = tuberculosis.
*: percentage of HIV-infected subjects.
Distribution of TB cases according to age and originFigure 1
Distribution of TB cases according to age and origin. 
Dark bars: foreign-born (n = 212, 84%); white bars: indige-
nous (Swiss-born) population (n = 40, 16%).Page 3 of 8
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Clinical presentation is summarized in Table 2. TB was
pulmonary (TBP) in 158 cases (63%) (TBP only: n = 115,
46%), extra-pulmonary (TBE) in 137 cases (54%) (TBE
only: n = 94, 37%), and both (TBP+TBE) in 43 cases
(17%). More than half of the extra-pulmonary cases had
adenitis (n = 74, 54%).
Table 3 describes the clinical presentation of TB according
to socio-demographic characteristics of patients. The odds
ratio of cavitary TB was markedly increased in smokers
(almost six times that of non-smokers), and decreased in
older subjects. Occurrence of extra-thoracic TB was associ-
ated with female gender but did not differ between for-
eign-born and indigenous patients. HIV co-infection, and,
to a lesser degree, alcohol dependence and female gender
were significantly associated with disseminated TB.
Diagnosis and diagnostic procedures
Mean time to diagnosis (i.e. time elapsed between first
symptoms recalled by the patient and beginning of treat-
ment) was 2.1 ± 3.1 months (range: 0-12, Figure 2) with-
out any statistical difference between the different groups
in terms of socio-demographic and clinical characteristics
in multivariate analysis. At diagnosis, of all patients, 10%
were asymptomatic and 35% had no general symptoms.
Figures 3 and 4 depict the relative contribution of sputum
and bronchoscopy for confirming the diagnosis of pulmo-
nary TB. All positive cultures were confirmed by PCR.
Bronchoscopy was performed in 24 of 26 subjects in
whom adequate sputum samples could not be obtained
and in 48 of the 59 sputum S- patients.
Among the 158 cases of pulmonary TB, most cases (n =
113, 71.5%) were diagnosed through sputum analysis
(smear+ (S+)/culture+ (C+): 72, S-/C+: 41 (figure 3); 7
cases were S-/C- (diagnosis was confirmed by extra-pul-
monary sampling). In 38 cases (24% of pulmonary TB: 24
patients in whom no sputum samples could be obtained
and 14 of the 48 S- patients), bacteriological confirmation
of pulmonary TB was obtained only by bronchoscopy
(bronchial aspirate: BA, and/or broncho-alveolar lavage:
BAL). Furthermore bronchoscopy samples were S+ in 12
sputum S- cases (diagnosis was confirmed by culture with
both procedures): in these 12 cases, bronchoscopy was a
time-saving procedure for confirming the clinical suspi-
cion of TB.
For the 48 patients who had bronchoscopy after S- spu-
tum, results of cultures for sputum, BA, and BAL are
shown in Figure 4. Positive culture rate was slightly higher
for BA (67%) and sputum (65%) than for BAL (54%).
Treatment and side effects
Drug-related side effects were noted in 75 cases (30%);
however, side effects severe enough to change or stop
treatment were reported in only 38 cases (15%): in 2/3 of
cases they were due to symptomatic liver test abnormali-
ties which occurred mainly within the first two months of
treatment (mean: 6.2 ± 7.3 weeks). Biological hepatitis
(6%) was associated with female gender (OR 9.1; 95% CI:
1.50-50), co-infection with HIV (OR 11.1, 95% CI: 2.34-
52.8) and alcohol abuse (OR 21.3; 95% CI: 1.6-283.8).
Other side effects reported were mainly general symptoms
(weight loss, vertigo, asthenia) (n = 20), rash (n = 17) and
neurological symptoms (polyneuropathy, n = 10). Proba-
bility of having a serious side effect was five-fold higher in
female patients (OR 4.76; 95% CI 1.85-12.5).
Resistance to at least one of the first line therapy drugs was
reported in 20 cases (8%). A previous treatment for TB
was highly associated with the risk of resistance (OR 13.6;
95% CI 2.02-91.9). Rate of multi-drug resistant TB (MDR-
TB) was 2%: all five cases were foreign-born. By univariate
analysis, MDR-TB was also associated with HIV co-infec-
tion and prior treatment for TB (p < 0.05). No XDR-TB
(extensively drug-resistant) case was detected.
Treatment was administered as a direct observed therapy
(DOT) in 47 cases (19%): multivariate analysis did not
disclose any significant differences between DOT and
non-DOT patients in terms of socio-demographic and
clinical characteristics or outcome.
Outcome
Table 4 summarizes causes of unsatisfactory outcome. Of
the 252 subjects included, treatment was completed in
210 (83%) cases. In 42 cases, (17%) follow-up was unsuc-
cessful. In multivariate analysis adjusted for age, sex, eth-
Table 2: Clinical presentation
n = 252 n (%)
Pulmonary TB 158 (63)
• Smear +/Culture + 93 (59)*
• Smear -/Culture + 58 (37)*
• Smear -/Culture - 7 (4)* #
• Cavitary disease 36 (23)*
• New TB cases 151 (96)*
Extrapulmonary TB 137 (54)
• Adenitis 74 (29)
• Pleuritis 18 (7)
• Abdominal TB 17 (7)
• Osteo-articular TB 17 (7)
• Urogenital tractus TB 16 (6)
• ENT TB 4 (2)
• Other 21 (8)
TB: tuberculosis; ENT = ear, nose and throat;
*: percentage of pulmonary TB cases; sputum or bronchoscopy 
samples.
Total number of cases exceeds 252 because multiple organ 
involvement possible.
#: Smear -/Culture -: diagnosis based on either positive culture or 
histopathology of other organ, and favourable radiological evolution 
of pulmonary involvement under treatmentPage 4 of 8
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substance abuse and clinical presentation (TBP, TBE), the
only factor that was significantly associated with unsuc-
cessful treatment outcome was male gender (OR 3.0; 95%
CI 1.04-8.64). Conversely, asylum seekers had a higher
probability of successful outcome (OR 0.05; 95% CI 0.01-
0.46). All five cases of MDR-TB were considered cured.
Relapse occurred in two cases; relapse rate was 0.24 per
100 patient-years occurring on average 2.5 ± 2.1 months
after completion of treatment. As shown, fatality rate was
1.6% (n = 4); none of these patients had a post-mortem.
Three cases were elderly patients with other co-morbidi-
ties which may have contributed to death.
According to WHO criteria, 87% of new cases of pulmo-
nary TB with a positive sputum smear (n = 68) and 80%
of those with a positive sputum culture (n = 144) had a
Table 3: Adjusted odd ratios for clinical presentation of TB according to socio-demographic characteristics of patients
Extra-pulmonary Tb Cavitary Tb Disseminated Tb
OR 95% CI OR 95% CI OR 95% CI
Age
▪ < 35 y 1.00 - 1.00 - 1.00 -
▪ 35-60 y 1.80 [0.91-3.55] 0.24 [0.08-0.73] 0.80 [0.31-2.07]
▪ ≥ 60 y 1.48 [0.57-3.90] 0.13 [0.03-0.62] 0.69 [0.15-3.30]
Male gender 0.38 [0.20-0.70] 0.68 [0.28-1.64] 0.31 [0.12-0.81]
Ethnic origin
▪ Caucasian 1.00 - 1.00 - 1.00 -
▪ Asian 2.18 [0.62-7.65] 0.72 [0.12-4.26] 1.79 [0.28-11.36]
▪ Hispanic 1.48 [0.51-4.25] 0.82 [0.21-3.18] 1.34 [0.26-6.95]
▪ Black 1.47 [0.59-3.71] 0.76 [0.23-2.48] 1.34 [0.30-5.94]
Swiss born 1.05 [0.37-2.97] 2.93 [0.80-10.72] 0.91 [0.17-4.78]
Co-infected with HIV 2.20 [0.86-5.60] 0.11 [0.01-1.06] 7.28 [2.45-21.60]
Active smoker 0.38 [0.14-1.02] 5.80 [1.85-18.17] 0.88 [0.20-3.91]
Alcohol abuse 0.52 [0.10-2.65] 0.56 [0.10-3.04] * *
CI = confidence interval; OR = odd ratio,* dropped: predicts failure perfectly
Kaplan Meier curve describing time to diagnosis: time elapsed (in months) betwe n beginning of symptoms and beginning ofa tituberculosis therapyFigure 2
Kaplan Meier curve describing time to diagnosis: 
time elapsed (in months) between beginning of 
symptoms and beginning of antituberculosis therapy. 
One case is not represented here: it was a young female 
patient who was unsuccessfully treated with several antibiot-
ics for slowly evolving atypical cutaneous lesions until a 
biopsy was performed after 24 months yielding a diagnosis of 
TB.
Diagnostic procedures for bacteriological confirmation of tuberculosis in 158 ca es of pulmonary TBFigure 3
Diagnostic procedures for bacteriological confirma-
tion of tuberculosis in 158 cases of pulmonary TB. 113 
cases were diagnosed through sputum analysis: 72 S+/C+ and 
41 S-/C+. *: of 48 subjects who had bronchoscopy because of 
S- sputum samples, 31 had positive sputum cultures; for 14 
subjects, only samples obtained by bronchoscopy were cul-
ture positive; 12 bronchoscopy samples were S+. **: S-/C- 
cases; diagnosis was confirmed in these cases either by histo-
pathological examination or culture of non-respiratory sam-
ples.Page 5 of 8
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ate analysis adjusted for age, sex, ethnic origin, HIV co-
infection, socioeconomic status, substance abuse and
clinical presentation (TBP, TBE) did not identify any risk
factor associated with an unfavourable outcome.
Discussion
This study describes the clinical and social characteristics
of patients with TB and their outcome over a 4-year period
in a low incidence area for TB, with a high immigrant pop-
ulation. Our main findings are: 1/TB in our area is essen-
tially a disease of young foreign-born subjects (84%). This
proportion is well above the 40-60% of foreign-born sub-
jects reported in most low-incidence countries. Indige-
nous cases are significantly older [11-14]; 2/Prevalence of
HIV co-infection was higher than previously reported in
our country (11%), and in Western Europe; 3/Extra-pul-
monary TB (TBE) was frequent (54%), and, more specifi-
cally, lymphadenitis. Surprisingly, lymphadenitis was not
associated with ethnic origin, age or HIV infection but
occurred more frequently in females; 4/Interestingly, cav-
itary TB was strongly related to smoking history, and
occurred less frequently in elderly patients; 5/Although
most cases of pulmonary TB were diagnosed through spu-
tum analysis, bacteriological confirmation of TB was
obtained by bronchoscopy only in 38 subjects (24% of all
pulmonary TB); 6/Side effects severe enough to change
treatment (15% of all cases) occurred more frequently in
female subjects; 7/Time to diagnosis remains disturbingly
long. Finally, applying WHO criteria to new sputum
smear positive pulmonary cases only, treatment success
rate for the 1999-2003 period was 87%, i.e. above the
85% success target set by WHO.
The very high proportion of young foreign-born subjects
among TB cases reported in our area reflects trends
recently reported in several countries of Western Europe,
and in Canada [15]. In Switzerland, the number of cases
of tuberculosis among foreign-born subjects (64% in
2004) exceeds that of native subjects since 1994, and,
although TB incidence in the indigenous population con-
tinues to decrease, the linear decline of tuberculosis noti-
fication observed since 1990 has markedly subsided since
2000 [4]. Similarly, between 2001 and 2005 in Norway,
Denmark, Sweden, Ireland, and Great Britain, increase in
TB among foreign-born subjects has been such that
national TB notification rates have in fact increased [2,3].
In this study, prevalence of HIV co-infection (11%) was
much higher than the 3% rate of HIV seropositivity
reported in TB patients in the WHO European region [16].
This rate is most probably influenced by the important
Results of cultures for mycobacteria of sputum samples, broncho-alveolar lavage (BAL) and br nchial aspirate (BA) in n = 48 subjec s in who  bronchoscopy was performed cause of neg tive microscopic an lysi  of s utu  smearsFig re 4
Results of cultures for mycobacteria of sputum sam-
ples, broncho-alveolar lavage (BAL) and bronchial 
aspirate (BA) in n = 48 subjects in whom bronchos-
copy was performed because of negative microscopic 
analysis of sputum smears. Three cases with negative cul-
ture of sputum, BAL and BA are not shown.
Table 4: Outcome of TB treatment adapted from WHO and IUATLD criteria [5]
Pulmonary C+ TB*
n = 144 (%)
Pulmonary S+ TB*
n = 68 (%)
†All cases TB
n = 252 (%)
Successful 115 (80) 59 (87) 210 (83)
Unsuccessful 29 (20) 9 (13) 42 (17)
Death 4 (2.8) 1 (1.5) 4 (1.6)
Treatment failure 1 (0.7) 1 (1.5) 2 (1)
Defaulters 6 (4) 0 (0) 8 (3)
Transfer out 18 (13) 7 (10) 28 (11)
Departure from country 13 4 23
Extradition 3 2 3
Follow-up by specialist or other hospital in Switzerland with no 
information available
2 1 2
C+ = culture positive; S+ = smear positive
*new cases of pulmonary TB
†WHO criteria do not apply to extrapulmonary TB: however, results for all TB cases are shown for comparisonPage 6 of 8
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rates of TB-HIV co-infection are very high [17,18]. Despite
a higher risk of disseminated disease [19], outcome was
not worse in subjects co-infected with HIV. An unexpected
observation, when compared to previous national reports
[4] is the presence of a substantial group of young Swiss-
born TB cases (< 50 yrs of age) in whom HIV infection was
highly prevalent (47%). National data estimate that only
2.6% of Swiss subjects with TB are co-infected with HIV,
vs. 20% in the present study; this observation is consistent
with an increase in TB/HIV co-infection recently reported
in England and Wales [20].
In our study, smokers had a 6-fold increase in risk of
developing cavitary TB; smoking was not associated how-
ever with a higher rate of smear positive sputum samples.
Smoking affects the clinical manifestations of TB by nota-
bly increasing occurrence of upper zone involvement, cav-
itary and miliary disease, and rate of positive sputum
cultures [21-23]. Suggested mechanisms include
decreased immune response, and decreased production of
TNFα by macrophages [24]. Down regulation of macro-
phage TNF-α in the lungs may render the patient more
susceptible to the development of progressive and severe
disease. This mechanism was already described with the
use of anti-TNFα treatment [25].
Conversely, cavitary disease was less frequent in elderly
subjects. Clinical and radiological presentation of pulmo-
nary TB in older subjects is frequently atypical, with a
more frequent involvement of lower and middle lobes, of
miliary patterns, and, in several studies, less frequent cav-
itary lesions [26,27], although this latter observation
remains controversial [28].
Bacteriological confirmation of TB was obtained by bron-
choscopy only in 24% of all pulmonary TB. Several studies
have provided evidence supporting the use of sputum
induction in smear-negative pulmonary TB disease. This
procedure is safe, has a high diagnostic yield and is more
cost effective than bronchoscopy [29-31]. However, in
industrialized countries, the role of bronchoscopy among
patients with smear negative TB needs to be clarified. A
recent paper studying prospectively in asylum seekers in
Switzerland noted that the diagnostic yield is increased by
bronchoscopy and concluded that this procedure, when
available, is recommended for sputum smear negative TB
[32]. Although the design of the study does not allow a
formal evaluation of the yield of bronchoscopy, our
results clearly suggest that bronchoscopy when available,
is contributive for rapid bacteriological confirmation of
diagnosis in sputum smear negative pulmonary TB.
A main endpoint of our study was the outcome of TB
treatment (Table 4). For new cases of sputum smear posi-
tive pulmonary TB only, treatment success rate was 87%,
i.e. just above the WHO set target of 85%, and compared
favourably with results recently reported in the European
Community, which ranged from 70 to 80% [6,11-15]. A
recent study by Ditah et al. which focused on outcome of
TB treatment in the United Kingdom, suggested that
WHO outcome criteria were not adapted to low incidence
industrialized countries [33]. The same authors proposed
new criteria to analyse outcome among all patients with
TB (pulmonary and extrapulmonary) from a clinical per-
spective. Using these criteria, the rate of satisfactory out-
come for all TB cases would be closer to 85% instead of
83% (Table 4), thus within WHO targets; these results are
the best reported in our country since 1998 [7-9].
A few limitations of this study must be mentioned:
The retrospective nature of the study is a methodological
limitation although the fact that all patients followed at
our institution (78.5% of all cases notified in Geneva dur-
ing this period), were prospectively included in a compu-
terized database, and were followed at one centre
minimizes the risk of selection bias. Through systematic
reviewing of patient files, the good quality of the database
could be assessed. Outcome criteria follow international
standards, thus permitting comparison with other coun-
tries [6,7,12-14,33]. For some associations and OR com-
putations, confidence intervals were wide due to small
sample size.
Finally, our protocol does not allow a retrospective assess-
ment of whether sputum samples analysed were sponta-
neous or induced, and thus a separate analysis of the
relative contribution of these samples. The vast majority
of patients suspected of TB in our area are referred to the
emergency ward of our hospital, or evaluated in a hospital
ward. When spontaneous sputum was not obtained, spu-
tum induction was systematically performed by chest
therapists, but samples processed by the laboratory do not
bear the mention of how they were obtained.
Conclusion
This study illustrates the present situation of TB in a low
incidence industrialized country: TB patients are mostly
young, foreign-born, with a high incidence of extra-tho-
racic involvement (mainly adenitis). Rate of co-infection
with HIV was higher in Switzerland than reported in the
WHO European region, and is a major risk factor for the
younger indigenous cases described. For smear positive
pulmonary TB, the 85% WHO target for successful out-
come has been reached.
With one third of patients who do not report suggestive
general symptoms, diagnosis of TB remains a challenge
for clinicians: indeed time to diagnosis remains disturb-
ingly long. The strong association between cavitary TB andPage 7 of 8
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negative TB warrant further investigation.
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